Acceleron said it will start the first regenerative therapeutic to enter human clinical trials from Acceleron's scientific platform that utilizes the body's own naturally-occurring growth factors. “Based on
The healthcare company said the FDA cleared the test, called EHIV (HIV Enhanced), which it hopes to sell under a business arrangement with US-based healthcare company Johnson &
In the clinical studies, presented at the SLEEP 20th anniversary meeting of the Associated Professional Sleep Societies, electroencephalogram (EEG) analyses showed that gaboxadol (5, 10, 15 and 20mg)
Acomplia is specifically indicated as an adjunct to diet and exercise for the treatment of obese or overweight patients with associated risk factors, such as type 2 diabetes
MORAb-003 is currently being evaluated in a phase II efficacy study in patients with platinum sensitive ovarian cancer. Phase I data have shown that the drug is well-tolerated
The Quebec-based company announced that during a recent end of phase II meeting, the FDA reviewed the safety and efficacy data from an extensive phase II program with
The groups have formed the European Partnership for Alternative Approaches to Animal Testing (EPAA), and committed to a five-year plan to reduce animal testing in product-safety checks. The
The filing is based on long-term data from two double-blind, placebo-controlled trials showing inhibition of structural damage and sustained improvement in functional status. Psoriatic arthritis is a chronic,
The deal includes an upfront cash payment of $5 million, but Cellera will only receive the $360 million if the program meets all developmental and commercial milestone events
Orphan drug designation provides companies with financial and regulatory benefits during the course of the drug development including tax credits related to clinical trial expenses and a possible
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.